论文部分内容阅读
目的测定2型糖尿病(T2DM)患者血浆成纤维细胞生长因子21(FGF-21)的浓度,观察罗格列酮对FGF-21的影响。方法 34例单用二甲双胍降糖治疗无效的T2DM患者加用罗格列酮(RGZ组)治疗12周,治疗前后测定FGF-21及相关代谢指标。同时测定初发2型糖尿病(T2DM组)30例,正常对照组(NC组)30例。结果 RGZ组和T2DM组FGF-21水平均高于NC组(P均<0.05),但两组间差异无统计学意义。联合治疗后,RGZ组血浆FGF-21水平显著降低(1.59±0.11 vs.1.87±0.11,P<0.05)。结论 FGF-21可能在罗格列酮调节代谢的机制中具有重要作用。
Objective To determine the concentration of fibroblast growth factor-21 (FGF-21) in patients with type 2 diabetes mellitus (T2DM) and to observe the effect of rosiglitazone on FGF-21. Methods 34 patients with T2DM treated with metformin hypoglycemic therapy were treated with rosiglitazone (RGZ) for 12 weeks. FGF-21 and related metabolic parameters were measured before and after treatment. Thirty newborns with type 2 diabetes mellitus (T2DM) and 30 normal controls (NC group) were also determined. Results The levels of FGF-21 in RGZ group and T2DM group were higher than those in NC group (all P <0.05), but there was no significant difference between the two groups. After the combination therapy, the level of plasma FGF-21 in RGZ group was significantly decreased (1.59 ± 0.11 vs 1.87 ± 0.11, P <0.05). Conclusion FGF-21 may play an important role in the mechanism of rosiglitazone in regulating metabolism.